MS and Demyelinating Disorders

Ahmed Zayed Obeidat MD, PhD, and Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, discuss the use of oral cladribine in the treatment of MS.

Experts in neurology present long-term efficacy and safety data of oral DMTs in the treatment of MS and share their perspective on the real-world significance.

The chair of the Department of Neurology at Cedars Sinai Medical Center discussed the prominent topics of research in multiple sclerosis and the need to learn more about age and sex. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease (PD).

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 31, 2023.

The neuroophthalmologist at Mayo Clinic discussed the current understanding of optic neuritis in neuromyelitis optica and the ways clinicians are working to improve recovery. [WATCH TIME: 4 minutes]

Foralumab, a fully human anti-CD3 monoclonal antibody, has had treatment effect demonstrated in patients with COVID-19 and with multiple sclerosis, as well as in healthy normal individuals.

Michael Levy, MD, PhD, associate professor at Harvard Medical School, talked about the differences between multiple sclerosis and neuromyelitis optica spectrum disorder, the currently available treatments, and next steps in research.

Disease activity, severity, or effect of treatment in patients with NMOSD may be predicted by aminoacyl-tRNA synthetase-interacting multifunctional protein-1.

The neuroophthalmologist at mayo clinic provided context on the importance of raising awareness for NMOSD and the signs that precede clinical events. [WATCH TIME: 3 minutes]

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, comments on the different modes of administration of DMTs in MS, focusing on oral DMTs.

Experts in neurology assess the risk of disease progression in a patient with MS and identify various biomarkers and diagnostic tools used to detect this.

Elaine Kingwell, PhD, senior research associate at University College London provided perspective on a study presented at the 2023 ACTRIMS Forum on HIV and multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 24, 2023.

Drs Ahmed Zayed Obeidat and Mark S. Freedman share considerations for individualized therapy for the management of MS.

Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of disease-modifying therapies for the treatment of multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 17, 2023.

The director of the Visual Outcomes Laboratory at Cedars Sinai talked about the current treatments used in MS and the risks associated with them at 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

The neurologist at Mayo Clinic, in Jacksonville, Florida, spoke about inebilizumab as a treatment for NMOSD and other autoimmune diseases, such as encephalitis, in the ExTINGUISH trial. [WATCH TIME: 3 minutes]

In honor of Brain Awareness Week, held March 13, 2023, to March 19, 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.